ARCHIVES

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

This article is from The Cancer Letter archive.

Vol. 24 No. 03 | January 23, 1998

Download PDF Visit The Full Archive

Related Articles

In Brief: NASA Procurement Specialist Names NEW NCI Contracts Chief; NIH Delays CREG Approval

January 3, 1975

After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA

April 14, 1995

Report Backs EPA Classification of PERC as Likely Human Carcinogen

February 12, 2010

NIH reauthorization to be topic of July 19 hearing.

July 15, 2005

Avastin Phase III Trial Meets Endpoint: PFS in Platinum-Sensitive Ovarian Cancer

February 25, 2011

Abbott To Supply Quest With Immunoassay Tests.

September 29, 2000